pharmaceuticals

The U.S. has been slower to adopt biosimilar drugs since the first such medicine was approved in 2015.

Many stakeholders agree that Biden's foot-dragging on finding a new director has sent the wrong message about the agency's importance.

The House probe focuses on conflicts of interest held by members of a committee currently reviewing U.S. organ donation and...

TJC is asking for your input on the changes as part of a standard field review.

Paying for high-cost, breakthrough drugs is one of healthcare's abiding challenges?and tied to so many of the "pre-existing" conditions that...

The massive spending bill is the first of two likely to at least delay the so-called Medicare rebate rule released...

Ultimately, the question of whether a booster is needed is unlikely to determine the FDA?s decision.

The requests received for data became more complex, requiring some to move away from just patient use data and incorporate...

Though patients will start taking it, the world may have to wait many years to find out whether Aduhelm is...

Faced with criticism over insufficient guidance, the FDA has revised the drug's label to narrow its potential use.

The diabetes care announcement marks the latest healthcare foray by the retail giant.

State officials estimate the combined impact of the various measures could save Coloradans between 20% and 40% in out-of-pocket costs.